GDUFA Facility Fees Will Be Significantly Higher Than Expected
This article was originally published in The Pink Sheet Daily
Executive Summary
Fewer fee-paying facilities than estimated self-identified with the agency as part of the launch of the generic drug user fee program, which helped increase the fees about 17% more than anticipated for domestic finished dosage form facilities.
You may also be interested in...
US FDA Changes Data Source For GDUFA II Facility Fee Setting
Agency primarily uses application data instead of facility self-identification lists to determine FY 2018 generic drug user fees.
US FDA Changes Data Source For GDUFA II Facility Fee Setting
Agency primarily uses application data instead of facility self-identification lists to determine FY 2018 generic drug user fees.
Generic User Fee Hikes Could Disrupt US FDA Drug Pricing Campaign
New GDUFA program fee is high enough that sponsors may withdraw applications to reduce their fee exposure, agency estimates.